摘要
目的探讨艾司西酞普兰合并喹硫平改善难治性抑郁症患者症状及社会功能的效果。方法将81例难治性抑郁症患者随机分为研究组(艾司西酞普兰合并喹硫平系统治疗)和对照组(艾司西酞普兰系统治疗),共治疗4周。在基线及治疗后第1、2、4周末采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、社会功能缺陷量表(SDSS)及副反应量表(TESS)评定疗效及不良反应。结果在治疗后第1周末,研究组HAMD及HAMA评分较基线即有显著性降低(P<0.05),而对照组HAMD及HAMA评分在第4周末才有显著性降低(P<0.05)。治疗第1周末、第2周末及第4周末,研究组的HAMD及HAMA评分均显著低于对照组,差异均有显著性(P<0.05)。在治疗后第2周末,研究组SDSS总分较基线即有显著性降低(P<0.05),而对照组SDSS总分在第4周末才有显著性降低(P<0.05)。治疗第2周末及第4周末,研究组的SDSS总分均显著低于对照组,差异均有显著性(P<0.05)。两组均未出现严重不良反应。结论艾司西酞普兰合并喹硫平可有效、快速的改善难治性抑郁症患者的抑郁焦虑症状及社会功能。
Objective To explore the efficacy of escitalopram combined with quetiapine on clinical symptoms and social function in patients with refractory depression. Methods A total of 81 patients with refractory depression were randomly divided into study group treated with escitalopram combined with quetiapine and control group treated with escitalopram monotherapy for 4 weeks. All patients were assessed with Hamilton Depression Scale （HAMD） , Hamilton Anxiety Scale （HAMA）, Social Disability Screening Schedule （SDSS） and Treatment Emergent Side Effect Scale （TESS） at baseline and at the end of the 1st, 2nd, 4th week of the treatment. Results Compared with baseline, scores of HAMD and HAMA in study group decreased significantly at the 1 st weekend （ P 〈 0.05 ）, while in control group the significance appeared till at the 4th weekend （P 〈 0.05 ）. Scores of HAMD and HAMA in study group were significantly lower than those in control group at the 1 st, 2nd, 4th weekend of the treatment （ P 〈 0.05 ）. Compared with baseline, score of SDSS in study group decreased significantly at the 2nd weekend of treatment （ P 〈 0.05 ）, while in control group, score of SDSS decreased significantly till at the 4th weekend （P 〈 0.05 ）. At the 2nd and 4th weekend of treatment, scores of SDSS in study group were significantly lower than those in control group （ P 〈 0.05 ）. There were no severe side effects in both groups and no significant difference was found in side effects between the two groups （P 〉 0.05 ）. Conclusion Escitalopram combined with quetiapine is effective and safe in improving clinical symptoms and social function in patients with refractory depression. Moreover, the combination therapy takes effect rapidly.
出处
《精神医学杂志》
2013年第2期126-128,共3页
Journal of Psychiatry
